A Hong Kong-based developer of a catalog of urine-based tests for cancer, infectious diseases, women’s health and more has ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

Philips is launching a new clinical trial aimed at reducing the amount of radiation used during coronary procedures, with an ...

Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. | ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...